DW6012(Dasidiem tab. 10/100mg) — Competitive Intelligence Brief

DW6012(Dasidiem tab. 10/100mg) (DW6012(Dasidiem tab. 10/100mg)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tyrosine kinase inhibitor combination. Area: Oncology.

marketed Tyrosine kinase inhibitor combination BCR-ABL, SRC family kinases Oncology Small molecule

Target snapshot

DW6012(Dasidiem tab. 10/100mg) (DW6012(Dasidiem tab. 10/100mg)) — Dong Wha Pharmaceutical Co. Ltd.. DW6012 is a fixed-dose combination of dasatinib and another agent that inhibits tyrosine kinases to suppress abnormal cell proliferation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
DW6012(Dasidiem tab. 10/100mg) TARGET	DW6012(Dasidiem tab. 10/100mg)	Dong Wha Pharmaceutical Co. Ltd.	marketed	Tyrosine kinase inhibitor combination	BCR-ABL, SRC family kinases
Dasatinib Tablets	Dasatinib Tablets	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	marketed	BCR-ABL tyrosine kinase inhibitor	BCR-ABL, SRC family kinases
Tislelizumab and nintedanib	Tislelizumab and nintedanib	The Affiliated Hospital of Qingdao University	marketed	PD-1 inhibitor + tyrosine kinase inhibitor combination	PD-1 (tislelizumab); VEGFR, FGFR, PDGFR (nintedanib)
Camrelizumab and Apatinib	Camrelizumab and Apatinib	Chinese Academy of Medical Sciences	phase 3	PD-1 inhibitor + VEGFR2 tyrosine kinase inhibitor combination	PD-1 (camrelizumab); VEGFR2 (apatinib)
Combination PD-1/PD-L1 ICI + VEGFR-TKI	Combination PD-1/PD-L1 ICI + VEGFR-TKI	University Hospital, Bordeaux	phase 3	PD-1/PD-L1 inhibitor + VEGFR tyrosine kinase inhibitor combination	PD-1, PD-L1, VEGFR (vascular endothelial growth factor receptor)
Mercaptopurine, Imatinib	Mercaptopurine, Imatinib	St. Jude Children's Research Hospital	phase 3	Purine analog antimetabolite and tyrosine kinase inhibitor combination	Purine metabolism enzymes (mercaptopurine); BCR-ABL, c-KIT, PDGFR (imatinib)
ASKC202+ Limertinib	ASKC202+ Limertinib	Jiangsu Aosaikang Pharmaceutical Co., Ltd.	phase 3	Bispecific antibody + third-generation EGFR tyrosine kinase inhibitor combination	EGFR (epidermal growth factor receptor) and c-MET (mesenchymal-epithelial transition factor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tyrosine kinase inhibitor combination class)

1. Dong Wha Pharmaceutical Co. Ltd. · 1 drug in this class
2. Hutchison Medipharma Limited · 1 drug in this class